AR131237A1 - Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma - Google Patents

Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma

Info

Publication number
AR131237A1
AR131237A1 ARP230103264A ARP230103264A AR131237A1 AR 131237 A1 AR131237 A1 AR 131237A1 AR P230103264 A ARP230103264 A AR P230103264A AR P230103264 A ARP230103264 A AR P230103264A AR 131237 A1 AR131237 A1 AR 131237A1
Authority
AR
Argentina
Prior art keywords
vegf
specifically binds
ang2
formulation
binding molecule
Prior art date
Application number
ARP230103264A
Other languages
English (en)
Inventor
Yi Liu
Bing He
Yidong Ma
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of AR131237A1 publication Critical patent/AR131237A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una formulación que comprende una molécula de unión biespecífica que se une a VEGF y a Ang2 y usos de la misma, y en particular a una formulación farmacéutica que comprende la molécula de unión biespecífica, un buffer, un estabilizante y un surfactante. Adicionalmente, la presente invención se relaciona además con el uso terapéutico o profiláctico de estas formulaciones. Reivindicación 1: Una formulación líquida, que comprende: (i) una molécula de unión biespecífica que se une específicamente a VEGF A y Ang2; (ii) un buffer; (iii) un estabilizante, y (iv) un surfactante, en donde el pH de la formulación de anticuerpo es aproximadamente 5,0 - 7,5, la molécula de unión biespecífica comprende una primera región de unión a diana que se une específicamente a VEGF A y una segunda región de unión a diana que se une específicamente a Ang2, en donde la segunda región de unión a diana es un VHH anti-Ang2 que comprende 3 CDRs: HCDR1, HCDR2, y HCDR3, en donde la HCDR1 comprende o consiste en una secuencia establecida en SEQ ID Nº 16; la HCDR2 comprende o consiste en una secuencia establecida en SEQ ID Nº 17 o 20; y la HCDR3 comprende o consiste en una secuencia establecida en SEQ ID Nº 18; opcionalmente, en donde la primera región de unión a diana está seleccionada de: un VHH que se une específicamente a VEGF A; un fragmento de unión a antígeno de un anticuerpo, por ej., un scFv, que se une específicamente a VEGF A, por ejemplo, el anticuerpo es un anticuerpo totalmente humano o humanizado; o un receptor de VEGF (VEGF R) que se une específicamente a VEGF A o a un dominio extracelular del mismo o una proteína de fusión que comprende el dominio extracelular del mismo, por ej., una proteína de fusión del dominio extracelular del mismo con un Fc. Reivindicación 27: Una formulación sólida obtenida mediante solidificación de la formulación líquida de acuerdo con una cualquiera de las reivindicaciones 1 - 26, en donde la formulación sólida está, por ej., en la forma de un polvo liofilizado para inyección. Reivindicación 28: Un dispositivo para administración, que comprende la formulación líquida de acuerdo con una cualquiera de las reivindicaciones 1 - 26 o la formulación sólida de acuerdo con la reivindicación 27, por ej., en la forma de una jeringa pre-llenada.
ARP230103264A 2022-12-01 2023-11-30 Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma AR131237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211545721 2022-12-01

Publications (1)

Publication Number Publication Date
AR131237A1 true AR131237A1 (es) 2025-02-26

Family

ID=91323042

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103264A AR131237A1 (es) 2022-12-01 2023-11-30 Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma

Country Status (10)

Country Link
EP (1) EP4628097A1 (es)
JP (1) JP2025539445A (es)
KR (1) KR20250140055A (es)
CN (1) CN120302997A (es)
AR (1) AR131237A1 (es)
AU (1) AU2023404529A1 (es)
IL (1) IL321122A (es)
MX (1) MX2025006354A (es)
TW (1) TW202426052A (es)
WO (1) WO2024114746A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121517578A (zh) * 2024-08-13 2026-02-13 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
WO2022059800A1 (en) * 2020-09-15 2022-03-24 Santen Pharmaceutical Co., Ltd. Bispecific binding molecules against vegf and ang2
TW202221027A (zh) * 2020-09-17 2022-06-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｖｅｇｆ和ａｎｇ－２的雙特異性抗原結合分子
CN117500828A (zh) * 2021-06-04 2024-02-02 信达生物制药(苏州)有限公司 结合VEGF和Ang2的双特异性结合分子以及其用途

Also Published As

Publication number Publication date
JP2025539445A (ja) 2025-12-05
IL321122A (en) 2025-07-01
EP4628097A1 (en) 2025-10-08
WO2024114746A1 (zh) 2024-06-06
KR20250140055A (ko) 2025-09-24
CN120302997A (zh) 2025-07-11
AU2023404529A1 (en) 2025-07-10
TW202426052A (zh) 2024-07-01
MX2025006354A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
AU2018348429B2 (en) Multispecific antibody
BR112020017530A2 (pt) Anticorpos anti-tigit e usos dos mesmos
AU2019262953B2 (en) Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
CN112334482A (zh) 用于癌症治疗的抗oxMIF/抗CD3抗体
US20180106790A1 (en) Single chain proteins with c-terminal modifications
RU2015144105A (ru) Антитела к гепсидину и их применения
JP2016513664A5 (es)
KR20230125238A (ko) Il-4r 및 il-31에 대한 특이성을 갖는 다중특이적 항체
CA3290882A1 (en) Anti-CD63 Antibodies, Conjugates, and Uses Thereof
PE20221256A1 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
KR102754842B1 (ko) 신규 항 hsa 항체
US20230089926A1 (en) Antibodies Conjugated with Fatty Acid Molecules and Uses Thereof
PE20231187A1 (es) Anticuerpos anti-par-2 y metodos de uso de los mismos
BR112020016469A2 (pt) Anticorpos do receptor anti-folato 1 e seus usos
CA3207791A1 (en) Anti-cd112r antibody and use thereof
PE20230682A1 (es) Anticuerpo anti-ox40 y usos del mismo
AU2019263432B2 (en) Antibody specifically binding to c-Met, and use thereof
CN113412121A (zh) 使用双特异性抗体结合补体和靶抗原的组合物和方法
KR20240118746A (ko) 항-cd47-cldn18.2 이중특이적 항체 및 이의 용도
KR20230078152A (ko) Psma에 특이적으로 결합하는 항체 및 그의 용도
WO2023029089A1 (zh) 抗cd3人源化抗体
KR20180119676A (ko) 포도칼릭신 및 tra-관련된 항체, 생산 방법 및 항암 치료제로서의 용도
CN117440970A (zh) 抗nectin-4抗体及其用途
CN117500832A (zh) 抗her3抗体、含有该抗体的抗体药物缀合物及其用途
US20240092942A1 (en) Trimeric polypeptides and uses thereof in the treatment of cancer